Tech Transfer eNews Blog

Bristol Myers Squibb and The Rockefeller University sign license agreement over COVID-19 treatment


By Jesse Schwartz
Published: February 10th, 2021

Bristol Myers Squibb and The Rockefeller University have entered into a license agreement to advance an antibody treatment for COVID-19.

Developed by a Rockefeller research team, the monoclonal antibody (mAb) duo treatment neutralizes SARS-CoV-2 for therapy or prevention of the novel coronavirus. The mAbs have been engineered to be highly potent and stable, allowing them to last longer in the bloodstream. In addition, because of its potency, the treatment only requires a low-dose subcutaneous administration, eliminating the need for intravenous infusion.

Together, these advantages could help expand access to COVID-19 treatment globally, including to low- and middle-income countries and communities where healthcare resources are limited.

Under the exclusive global license agreement, Bristol Myers Squibb will support Rockefeller in its further development and studies of the treatment. If the development is successful, the company will work to enable availability and affordability of the treatment to patients worldwide. Rockefeller will be entitled to receive royalty payments on future sales.

“New treatment options are urgently needed that treat mild to moderate disease and prevent development of severe disease in high-risk patients,” says Richard P. Lifton, president of Rockefeller. “Our collaboration with BMS will help us accelerate development timelines and support rapid delivery to patients.”

“We look forward to continuing to work with The Rockefeller University in this crucial effort,” says Ho Sung Cho, senior vice president of Discovery Biotherapeutics at Bristol Myers Squibb. “We are committed to leveraging our capabilities and resources in an effort to expeditiously develop and bring this potential treatment to patients and further address the challenges of the pandemic.”

Source: MarketWatch

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment